Clinical Trial

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Pumitamig in participants with Relapsed/Refractory Small Cell Lung Cancer
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2026-01-06; most recent amendment 2026-07-16.
Status change: Not Yet Recruiting → Recruiting 2026-02-17
Trial Details
NCT Number NCT07325136
Lead Sponsor Bristol-Myers Squibb
Conditions Relapsed/Refractory Small Cell Lung Cancer
Enrollment 240 participants
Start Date 2026-02-03
Primary Completion 2029-04-23 (estimated)
Study Completion 2029-04-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-17